

Appendix A: Guideline Development Group and Service Delivery Group (SDG) Declarations of Interest, 2015

Declarations of Interest were managed against the NICE Conflicts of Interest Policy, 2007.

| GDG member | Interest Declared | Declared when? | Type of Interest | Decisions Taken |
|---------------------|---|----------------|---|-------------------------|
| Ibrahim Abubakar | Chief investigator for the NIHR funded study on the prognostic value of IGRAs (this call was suggested by the Department of Health as a response to the recommendations of NICE clinical guidelines 33) and a co-applicant on a NIHR funded systematic review and economic analysis on genetic tests for the rapid detection of resistance to anti TB drugs. I have recently been funded by the Department of Health to conduct a randomised controlled trial to improve the diagnosis of latent TB using peer support workers and another trial of rifapentine for latent TB. The research is fully funded by the Department of Health/NHS with no commercial involvement. | September 2012 | Non-personal financial, specific interest | Declare and participate |
| Timothy Collyns | Employer - LTHT Microbiology, has received small amounts of funding to enable local evaluation of certain diagnostic methods | January 2013 | Non-personal financial, non-specific interest | Declare and participate |
| Francis Drobniowski | Health Consultancy training grant (from Otsuka Pharmaceutical, Japan) to train Indonesian doctors in UK. This included training on clinical TB and laboratory management and practice, evidence based medicine, role of NICE, JCVI and other bodies. | January 2013 | Non-personal financial, specific interest | Declare and participate |

| GDG member | Interest Declared | Declared when? | Type of Interest | Decisions Taken |
|---------------------|--|-----------------------|---|-------------------------|
| Francis Drobniowski | PI HTA grant relating to Diagnosis of drug resistant TB 2012-13 | January 2013 | Non-personal financial, specific interest | Declare and participate |
| Francis Drobniowski | Co-PI EU FP7 grant from PANNNET who implements diagnostic and clinical trials network in Eastern Europe | January 2013 | Non-personal financial, specific interest | Declare and participate |
| Andrew Hayward | Part of a research project on identifying and managing tuberculosis in hard to reach groups, which has received a loan of a CEPHEID gene-expert machine and donation of diagnostic kits to assess the value of the technology as a near patient test on the mobile X ray unit. | October 2012 | Non-personal financial, non-specific interest | Declare and participate |
| Uday Katkar | Director of a Limited Company – Dr Katkar Limited, which only deals with locum and other non pensionable work. There is no pecuniary interest with the GDG work | May 2014 | Personal financial, non-specific interest | Declare and participate |
| Uday Katkar | Full time, self-employed, GP Locum since 1 st April 2014 | May 2014 | Personal financial, non-specific interest | Declare and participate |
| Marc Lipman | Received remuneration for attending an NAPP Advisory Board for Flutiform (asthma product) in May 2012. Remuneration was paid into a research grant. | April 2013 | Non-personal financial, non-specific interest | Declare and participate |
| Marc Lipman | Invited speaker at ZINC (UK HIV Specialist Pharmacists Group, sponsored by BMS), presentation on HIV & TB, June 2013. Remuneration paid into Research Grant. | April 2013 | Non-personal financial, specific interest | Declare and participate |
| Marc Lipman | Member of international expert panel working on definitions of Opportunistic infections in patients receiving biological agents, including TB. Project duration January - May 2014. Organised by Reynolds Clinical Sciences with sponsorship by pharmaceutical | January 2014 | Non-personal financial, specific interest | Declare and participate |

| GDG member | Interest Declared | Declared when? | Type of Interest | Decisions Taken |
|-------------|--|----------------|---|-------------------------|
| | industry. Remuneration paid into Research Grant. | | | |
| Marc Lipman | Advisory board for Prevenar (Pfizer pneumococcal vaccine) use in HIV infection, June 2014. Remuneration paid into Research Grant. | September 2014 | Non-personal financial, non-specific interest | Declare and participate |
| Marc Lipman | Advisory board for Cardiovascular risk assessment in HIV, sponsored by Gilead, July 2014. Remuneration paid into Research Grant. | September 2014 | Non-personal financial, non-specific interest | Declare and participate |
| Marc Lipman | From July 2014 onwards - Consultancy work via UCL with ProteinLogic (start up medical diagnostic company). Area of interest is TB diagnosis using blood based proteins. Uncertain volume of work, though likely to be minimal in first 12 months. Any remuneration will be paid into a Research Grant. | September 2014 | Non-personal financial, specific interest | Declare and participate |
| Marc Lipman | Grants for: <ul style="list-style-type: none"> NIHR HTA assessment of (1) value of rapid molecular diagnostics and (2) BCG Dept of Health evaluation of long acting rifamycin (rifapentine) for treatment of latent TB infection. | April 2013 | Non-personal financial, specific interest | Declare and participate |
| Marc Lipman | Independent member of NIHR Programme Grant Trial Steering Committee for “Development of an optimal antibiotic regimen for long-term therapy in stable COPD” | April 2013 | Non-personal financial, non-specific interest | Declare and participate |
| Marc Lipman | Member of HPA Respiratory Infection Programme Board who sign off position statements on aspects of TB | April 2013 | Personal non-financial, specific interest | Declare and participate |
| Marc Lipman | Member of HPA National Knowledge Service for TB who produce information on TB for healthcare | April 2013 | Personal non-financial, specific interest | Declare and participate |

| GDG member | Interest Declared | Declared when? | Type of Interest | Decisions Taken |
|--|---|-----------------------|---|-------------------------|
| | workers and the general public. | | | |
| Marc Lipman | Member of European Centre for Disease Prevention and Control, MDR TB panel (2011-12) produced guidance on the management of MDR TB latently infected contacts. | April 2013 | Personal non-financial, specific interest | Declare and participate |
| Marc Lipman | Attended American Thoracic Society Meeting 2012 & European Respiratory Society Meeting 2012 with support of NAPP pharmaceuticals. | April 2013 | Non-personal financial, specific | Declare and participate |
| Marc Lipman | Clinical expert for European Medicines Agency Committee for Medicinal Products for Human Use, Anti-infectives Specialist Advisory Group on Delamanid (new anti-TB drug produced by Otsuka), March 2013 | April 2013 | Personal non-financial, specific interest | Declare and participate |
| Marc Lipman | ERS/WHO Consilium Clinical Expert for MDR TB (2013 -) | April 2013 | Personal non-financial, specific interest | Declare and participate |
| Marc Lipman | Involvement in Studies of new blood TB IGRA assay use in latent and active TB (Qiagen manufacturers of Quantiferon). These are both investigator-led (free kits supplied with no other remuneration) and commercial (company provide research nurse, there is no direct financial payment). I am not lead investigator on these studies but my team will recruit patients to these studies. Date July 2014 onwards. | September 2014 | Personal non-financial, specific interest | Declare and participate |
| Bertie Squire | Having previously worked with Jason Madden from Warwick Evidence, but not on the work Warwick Evidence have done for this guideline. | January 2015 | Personal non-financial, non-specific interest | Declare and participate |
| John Watson (co-opted expert Consultant Physician) | November 2014: Otsuka Pharmaceuticals (Manufacturer of | November 2014 | Personal financial, non-specific interest | Declare and participate |

| GDG member | Interest Declared | Declared when? | Type of Interest | Decisions Taken |
|---|---|----------------------|--|--------------------------------|
| | <p>Delaminid, new drug for MDR TB) paid me to act as a consultant for a single “expert council” meeting of European MDRTB specialists in Munich, 14/11/2014.</p> <p>(Note that in discussion of MDRTB, principles of treatment were discussed but individual drugs were not.)</p> | | | |
| <p>John Watson (co-opted expert Consultant Physician)</p> | <p>Member of British Thoracic Society MDRTB advisory service since 2008, and clinical lead for that service Nov 2010 - August 2014</p> <p>Member of British Thoracic Society TB Specialist Advisory Group for Tuberculosis 2008-2014</p> | <p>November 2014</p> | <p>Personal non-financial, specific interest</p> | <p>Declare and participate</p> |

A.1 Service Delivery Group (SDG) members

| Service Delivery Group member | Interest Declared | Declared when? | Type of Interest | Decisions Taken |
|--------------------------------------|--|----------------|--------------------------------------|-------------------------|
| Onn Min Kon | I have been on an Advisory Board of Janssen with respect to advice on Bedaquiline but have not personally received any financial reward for this | April 2014 | Personal non-financial, non-specific | Declare and participate |
| Onn Min Kon | I am the chair of the British Thoracic Society Specialist Advisory Group | April 2014 | Personal non-financial, non-specific | Declare and participate |
| Onn Min Kon | I am co-chair of the TB subgroup of the Respiratory Clinical Reference Group | April 2014 | Personal non-financial, non-specific | Declare and participate |
| Onn Min Kon | I have chaired and spoken at TB related educational seminars organised by Qiagen, Janssen and Otsuka but have not received any payment for these activities. | April 2014 | Personal non-financial, non-specific | Declare and participate |
| Expert advisers to sub-group: | | | | |
| Sue Ibbotson | Employee of Public Health England advocating in my role for a systematic approach to control of tuberculosis | September 2014 | Personal non-financial, non-specific | Declare and participate |
| Anton Pozniak | Chair of British HIV Association TB/HIV guidelines | January 2015 | Personal non-financial, non-specific | Declare and participate |
| Anton Pozniak | Member of British Thoracic Society joint committee on tuberculosis | January 2015 | Personal non-financial, non-specific | Declare and participate |
| Anton Pozniak | Member of Department of Health expert advisory group on AIDS | January 2015 | Personal non-financial, non-specific | Declare and participate |
| Anton Pozniak | Vice Chair of European AIDS Clinical Society clinical guidelines for HIV | January 2015 | Personal non-financial, non-specific | Declare and participate |
| Anton Pozniak | President of the European AIDS and Infectious disease treatment network | January 2015 | Personal non-financial, non-specific | Declare and participate |
| Anton Pozniak | Treasurer of the International AIDS society | January 2015 | Personal non-financial, non-specific | Declare and participate |
| Anton Pozniak | Panel member of the World Health Organization 2013 HIV guidelines | January 2015 | Personal non-financial, non-specific | Declare and participate |